API | duligotuzumab

duligotuzumab Report issue

Biologics mAb Multi-specific Experimental

AACT ChEMBL DrugBank

Active Ingredient History

NOW

Duligotuzumab (INN) is a bispecific humanized IgG1 monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and binds to EGFR and HER3. It is in development by Roche. Clinical development for head and neck cancer and colorectal cancer have been discontinued, but phase I trials in combination with cobimetinib are evaluating safety for treatment of solid tumors. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules:

None

duligotuzumab

More Chemistry

Pharmacology

Mechanisms of Action:
- Epidermal growth factor receptor (Homo sapiens) ^UniProt
- Receptor tyrosine-protein kinase erbB-3 (Homo sapiens) ^UniProt
- Epidermal growth factor receptor (Homo sapiens) ^UniProt
Multi-specific: Yes
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

duligotuzumab | mehd7945a | rg7597 | rg-7597

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)

Carcinoma (Phase 1)

Colorectal Neoplasms (Phase 2)

Head and Neck Neoplasms (Phase 2)

Neoplasms (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 5
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue